INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 81 filers reported holding INFINITY PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $55,251 | -34.4% | 262,473 | -50.1% | 0.00% | – |
Q1 2023 | $84,166 | -42.1% | 526,036 | +100.7% | 0.00% | – |
Q4 2022 | $145,487 | -53.4% | 262,138 | -0.1% | 0.00% | – |
Q3 2022 | $312,000 | +86.8% | 262,526 | -0.5% | 0.00% | – |
Q2 2022 | $167,000 | -44.3% | 263,878 | +0.2% | 0.00% | – |
Q1 2022 | $300,000 | +29900.0% | 263,467 | +35028.9% | 0.00% | – |
Q3 2019 | $1,000 | 0.0% | 750 | 0.0% | 0.00% | – |
Q2 2019 | $1,000 | 0.0% | 750 | 0.0% | 0.00% | – |
Q1 2019 | $1,000 | 0.0% | 750 | 0.0% | 0.00% | – |
Q4 2018 | $1,000 | -100.0% | 750 | -100.0% | 0.00% | -100.0% |
Q1 2018 | $7,535,000 | +3.4% | 3,588,249 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $7,284,000 | +1987.1% | 3,588,249 | +1513.6% | 0.00% | – |
Q2 2017 | $349,000 | -78.3% | 222,373 | -81.3% | 0.00% | – |
Q4 2016 | $1,605,000 | -10.3% | 1,188,976 | +3.7% | 0.00% | – |
Q3 2016 | $1,789,000 | +23.8% | 1,146,500 | +5.5% | 0.00% | – |
Q2 2016 | $1,445,000 | -88.4% | 1,086,500 | -54.1% | 0.00% | -100.0% |
Q1 2016 | $12,468,000 | -32.5% | 2,365,825 | +0.5% | 0.00% | 0.0% |
Q4 2015 | $18,472,000 | +4.3% | 2,353,167 | +12.2% | 0.00% | -33.3% |
Q3 2015 | $17,714,000 | -25.2% | 2,096,367 | -3.1% | 0.00% | 0.0% |
Q2 2015 | $23,695,000 | -29.6% | 2,163,948 | -10.1% | 0.00% | -25.0% |
Q1 2015 | $33,663,000 | -38.7% | 2,407,942 | -25.9% | 0.00% | -42.9% |
Q4 2014 | $54,913,000 | +21.3% | 3,251,242 | -3.6% | 0.01% | +16.7% |
Q3 2014 | $45,278,000 | -28.8% | 3,373,942 | -32.4% | 0.01% | -33.3% |
Q2 2014 | $63,575,000 | +18.3% | 4,990,187 | +10.4% | 0.01% | +28.6% |
Q1 2014 | $53,726,000 | -1.5% | 4,518,612 | +14.5% | 0.01% | -12.5% |
Q4 2013 | $54,521,000 | -53.2% | 3,947,866 | -40.8% | 0.01% | -55.6% |
Q3 2013 | $116,382,000 | -0.2% | 6,669,469 | -7.0% | 0.02% | -5.3% |
Q2 2013 | $116,578,000 | – | 7,174,041 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |